pipeline | autoimmune/inflammation | oncology
A Phase I healthy volunteer study for ALPN-101 is currently enrolling. ALPN-202 is targeted to file an IND or equivalent later in 2019.
Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2019 Financial Results. Our Q3 conferenc… twitter.com/i/web/status/11947…
November 13, 2019 9:12 pm
Yesterday and today we presented two posters with preclinical data supporting the potential for ALPN-101, our dual… twitter.com/i/web/status/11942…
November 12, 2019 12:34 pm
© 2019 Alpine Immune Sciences.
All Rights Reserved, Alpine Immune Sciences Inc.